NCT03541603Phase 2Completed

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Study sponsor: Tenax Therapeutics, Inc. · TENX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-04-07Actual
Enrollment · participants44Actual
Source updated2024-11-20Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.